Clinical trial
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type…
NCT00358150 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00358150 |
|---|---|
| Title | A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients |
| Official title | A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Non-Neuronopathic Form |
| Intervention type | Drug |
| Interventions | Eliglustat tartrate |
| Enrollment | 26 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Dec 1, 2015 |
| First posted | Jul 31, 2006 |
| Last update posted | Feb 15, 2017 |
| Countries | Argentina, Israel, Italy, Mexico, Russia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: